VTRNA2-1

Across TCGA pan-cancer cohorts, VTRNA2-1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated VTRNA2-1 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher VTRNA2-1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated VTRNA2-1 expression acts as an unfavorable survival marker.

THCA, CHOL, and SKCM are the cancer types where VTRNA2-1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.133	0.842	.001	12	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	OS	Median	IV	0.226	0.613	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

VTRNA2-1–THCA (DFS)

Open the THCA breakdown →